THERAPIES
-
Announcement of a clinical trial for Vioxx for people with hemophilia
(…) The pain drug became synonymous with pharmaceutical risk more than 15 years ago when studies revealed that it roughly doubled patients’ risk of heart...
-
European Haemophilia Consortium New Products Review
Read the latest research news about innovative coagulation products – factor replacement products, non-factor therapies and gene therapies – in the European Haemophilia Consortium New...
-
Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
-
A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a...
-
Access to Innovative and Curatives Therapies – NRBDO virtual conference
NOVEMBER 5-7 Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients? What is...